Henze, T. and Feneberg, W. and Flachenecker, P. and Seidel, D. and Albrecht, H. and Starck, M. and Meuth, S. G. (2017) What is new in symptomatic MS treatment: Part 2-gait disorder and spasticity. NERVENARZT, 88 (12). pp. 1428-1434. ISSN 0028-2804, 1433-0407
Full text not available from this repository. (Request a copy)Abstract
The symptomatic treatment of multiple sclerosis (MS) nowadays is of similar importance as immunotherapy within a comprehensive concept of therapy of this chronic disease, since it contributes considerably to the reduction of disabilities in activities of daily living as well as social and occupational life. Moreover, symptomatic treatment is of great importance for amelioration of quality of life. Since our last survey of symptomatic MS treatment in 2004 and publication of the guidelines of the German Neurological Society and the Klinisches Kompetenznetz Multiple Sklerose (KKNaEuroMS) in 2014 several developments within the topics of mobility, bladder and sexual function, vision, fatigue, cognition and rehabilitation took place. These new findings together with further aspects of disease measures and overall treatment strategies of the respective symptoms, as well as treatment goals are introduced in a series of six individual contributions. Here, the symptoms of gait disorders and spasticity will be discussed.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | QUALITY-OF-LIFE; MULTIPLE-SCLEROSIS; OROMUCOSAL SPRAY; SAFETY; NABIXIMOLS; EXERCISE; EFFICACY; ADULTS; DALFAMPRIDINE; METAANALYSIS; Multiple sclerosis; Symptomatic therapy; Review; Gait disorder; Spasticity |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 14 Dec 2018 13:19 |
| Last Modified: | 19 Feb 2019 07:11 |
| URI: | https://pred.uni-regensburg.de/id/eprint/1781 |
Actions (login required)
 |
View Item |
